Tricine (CAS:5704-04-1) is an excellent amphoteric biological good's buffer. The invention patent CN111084889A introduces the application of Tricine in radiochemistry and clinical nuclear medicine. The invention provides a preparation method of a nuclide molecular probe targeting CD4 receptor and its application as an imaging agent for cardiac transplant rejection. its specific technical solutions are as follows:

1.Monoclonal antibody pretreatment: put the desalting column into a centrifuge tube, centrifuge, discard the storage solution, add modification buffer to adjust the pH to 8, centrifuge, put the desalting column into a new centrifuge tube, and take the leukocyte differentiation antigen 4 monoclonal antibody and add it to the desalting column, centrifuge, and collect the purified cluster of differentiation 4 monoclonal antibody;

2. Mix Cluster of differentiation 4 monoclonal antibody with 6-hydrazinonicotinosuccinimide ester hydrochloride solution, 6-hydrazinonicotinosuccinimide ester hydrochloride in excess, the molar ratio of 6-hydrazinonicotinosuccinimide ester hydrochloride solution to antibody is (10-30): 1;

3. 6-hydrazinonicotinamide-leukocyte differentiation antigen 4 monoclonal antibody obtained by the extraction reaction;

4. Mix 6-hydrazinonicotinamide-leukocyte differentiation antigen 4 monoclonal antibody with Tricine (100-120mg/ml), stannous chloride (7-10mg/ml), technetium (radiation dose of 740-1110MBq);

5. Shake reaction at 4-5℃for 30-60 min in the dark.

The beneficial effects of this patent are:

1. It has a high labeling rate and radiochemical purity, and has a good affinity for CD4+ T lymphocytes;

2. As an imaging agent for transplant rejection, it has the characteristics of high sensitivity and high specificity, and can realize early diagnosis of acute rejection.

References

CN111084889A A preparation method of a radionuclide molecular probe targeting CD4 receptor and its application as an imaging agent for cardiac transplant rejection.